Ortiz-Gonzalez Xilma, Wierenga Klaas
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Mayo Clinic Florida, Jacksonville, Florida
disorder is typically characterized by severe-to-profound developmental delay and/or intellectual disability, although two individuals in one family had a milder phenotype, including one individual with normal cognitive development. Speech and language skills are often severely limited. Affected individuals rarely achieve head control. Most are unable to sit, stand, or walk. Affected individuals typically have congenital hypotonia that may transition to hypertonia. Axonal motor neuropathy leads to hyporeflexia/areflexia and weakness, which can result in respiratory difficulties requiring ventilatory support. Most affected individuals require tube feeding for nutrition. Half of affected individuals develop seizures. Cortical visual impairment and auditory neuropathy have also been reported.
DIAGNOSIS/TESTING: The diagnosis of disorder is established in a proband with congenital hypotonia and biallelic pathogenic (or likely pathogenic) variants in identified by molecular genetic testing.
: Hearing aids may be helpful for those with hearing loss; ventilator support (e.g., BiPAP) for respiratory distress; consideration of Robinul or Botox injections for severe sialorrhea; feeding therapy and consideration of gastrostomy tube placement for persistent feeding difficulties and/or concern about aspiration; standard treatment for developmental delay / intellectual disability, epilepsy, cortical vision impairment, constipation, and spasticity / joint contractures. Assessment for new neurologic manifestations and/or adequacy of seizure control, developmental progress, growth and nutritional status, constipation, and joint mobility at each visit; ophthalmology evaluation every one to two years in those with optic atrophy; audiology evaluation as clinically indicated; sleep study every one to two years.
disorder is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Once the pathogenic variants have been identified in an affected family member, carrier testing for at-risk relatives, prenatal testing for a pregnancy at increased risk, and preimplantation genetic testing are possible.
该病症通常以重度至极重度发育迟缓及/或智力残疾为特征,不过一个家族中的两名个体表现出较轻微的表型,其中一人认知发育正常。言语和语言技能往往严重受限。受影响个体很少能控制头部。大多数人无法坐、站或行走。受影响个体通常有先天性肌张力减退,可能会转变为肌张力亢进。轴索性运动神经病导致反射减退/无反射和肌无力,可引发呼吸困难,需要通气支持。大多数受影响个体需要通过鼻饲管获取营养。半数受影响个体出现癫痫发作。也有皮质视觉障碍和听觉神经病的报道。
诊断/检测:通过分子基因检测在患有先天性肌张力减退且在[相关基因]中存在双等位基因致病性(或可能致病性)变异的先证者中确立该病症的诊断。
对于听力损失者,助听器可能有帮助;对于呼吸窘迫,给予通气支持(如双水平气道正压通气);对于严重流涎,考虑使用东莨菪碱或肉毒杆菌毒素注射;进行喂养治疗,并考虑为持续存在喂养困难和/或担心误吸的患者放置胃造瘘管;对发育迟缓/智力残疾、癫痫、皮质视觉障碍、便秘以及痉挛/关节挛缩进行标准治疗。每次就诊时评估新的神经学表现和/或癫痫控制的充分性、发育进展、生长和营养状况、便秘以及关节活动度;对视神经萎缩患者每1至2年进行眼科评估;根据临床指征进行听力评估;每1至2年进行一次睡眠研究。
该病症以常染色体隐性方式遗传。在受孕时,受影响个体的每个同胞有25%的几率受到影响,50%的几率为无症状携带者,25%的几率不受影响且不是携带者。一旦在受影响的家庭成员中确定了[相关]致病性变异,就可以对有风险的亲属进行携带者检测、对高风险妊娠进行产前检测以及进行植入前基因检测。